BioSpace

In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm.

Host

⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Hans Eriksson, Chief Medical Officer, FundaMental Pharma

Steve Levine, Chief Patient Officer, Compass Pathways

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.

In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively.

This episode is presented in partnership with Arvinas.

Host

Jennifer Smith-Parker, Director of Insights, BioSpace

Guest

Randy Teel, President and CEO, Arvinas

The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics’ Duchenne muscular dystrophy therapy and Replimune’s advanced melanoma drug indicating an uphill battle for the biotechs; GSK and AstraZeneca outlined ambitious plans in second quarter presentations; Sarepta tapped Michael Severino as its new CEO; and Amgen launched its official defense of Tavneos.

In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Ester Sklarsky, Principal, Sound Bioventures

João Ribas, Partner, Novo Holdings Seed Investments

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.  

In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Lance Alstodt, Chairman & CEO, BioRestorative Therapies

Paul Mieyal, Chief Business Officer, South Rampart Pharma

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.

In this bonus episode, BioSpace Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss encouraging signs for job seekers.

In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Jack Crawford, CEO, Demeetra

Magnus Gustafsson, Chief Commercial Officer, NorthX Biologics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.